Downstream Bioprocessing: Companies, Startups & Research

Thermo Fisher Scientific, Merck Group, Sartorius AG, Pfizer and Lonza Group are among the companies active in downstream bioprocessing. Their work spans filtration, chromatography, viral safety, process equipment and biologics manufacturing. Novartis reports research on membrane chromatography, while AstraZeneca has reported high-throughput microscale chromatography methods for process characterization and control-strategy development.

The listed startups include Baiya Phytopharm Co., Inbiose and Mycosynthetix, Inc., each with a distinct purification focus. Baiya Phytopharm's associated research examines residual host-plant proteins in plant-produced biologics; Inbiose patents cover purification of fermentation-derived saccharides; and Mycosynthetix works on scaling production and purification of fungal metabolites. These profiles indicate specialized niches rather than broad supplier platforms.

Chinese Academy of Sciences CAS, Jiangnan University and the University of California are among the active research organizations. Their recorded window activity includes 307 documents for CAS, 300 for Jiangnan University and 216 for the University of California. Recent work includes fermentation-derived product recovery at CAS, high-purity thaumatin production at Jiangnan University and an automated plant-cell-pack pipeline at the University of California.

Recorded grants total $403,432,757 across 255 grants since 2020. This figure is the grant funding total in the available data, not a complete measure of corporate investment or facility spending. Funding-round records also report $147,277,664,418 across 41 rounds, but the listed entries include activity that is not clearly specific to downstream bioprocessing.

The Institute of Materia Medica, Chinese Academy of Medical Sciences, is the leading listed patent holder, with 20 patents. Regeneron Pharmaceuticals Inc has 17, followed by Sartorius AG with 12. Genentech and LanzaTech Inc. each have 10, while Fujifilm Co. has 9 and Cytiva has 8.

No: the recorded patent growth is negative, with 1,027 patents in the specified window. By contrast, publications grew 11.9% in the last year. The divergence suggests that research activity and patenting are moving differently; it does not by itself show whether technical progress or commercial adoption is accelerating.

Recent developments include Wuxi Biologics' automated purification study and the Transcenta Therapeutics–WuXi Biologics HiCB technology licensing agreement, both reported in September 2026. Fujifilm Biotechnologies unveiled ShunzymeX precision purification in March 2026. Recent research also explores plant-based screening pipelines, integrated continuous processing and methods to improve recovery of recombinant proteins.

The main approaches are harvest and clarification, chromatographic purification, membrane separations, viral safety, precipitation and extraction, and formulation and sterile processing. Chromatography accounts for 56.0% of patents in the approach data, while membrane separations account for 10.0%. These methods serve different functions: removing solids, separating product from impurities, managing viral risk or preparing the final product.

The United States leads the recorded activity, with 62,267 documents and a 50.4% share. China follows with 27,561 documents and a 22.3% share; the United Kingdom and Germany are also prominent, with 20,731 and 19,339 documents respectively. These figures describe recorded document activity, rather than a direct comparison of manufacturing capacity.

Applications include monoclonal antibodies, vaccines, gene therapies and viral vectors, recombinant proteins and enzymes, and fermentation-derived products. Monoclonal antibodies account for 7,365 documents, while recombinant proteins and enzymes account for 5,252. Gene therapies and viral vectors, which include complex particles requiring tailored purification, account for 3,597 documents.